Abstract
Previous studies have shown that microRNAs (miRNAs) are involved in the regulation of a variety of metabolic diseases, which related to some important signal pathways. Our aim was to explore the possible mechanism of miRNAs by revealing the differential expression of serum miRNAs in different BMI of type 2 diabetes mellitus (T2DM) patients with non-alcoholic fatty liver disease (NAFLD). We found that miR-29 decreased liver aminotransferase gamma-GGT and uric acid levels by inhibiting the expression of JNK-1 in non-obese T2DM patients with NAFLD, and down-regulated the expression of atherosclerosis-related factor lipoprotein phospholipase A2 (Lp-PLA2). Combined with bioinformatics analysis, we speculate that this may be mediated by the AMPK signaling. These findings suggest that miR-29 may be a potential targeted therapeutic strategy in T2DM patients with NAFLD.